CA2277430A1 - Systeme d'expression stable d'une phosphodiesterase de camp a affinite elevee et son utilisation - Google Patents
Systeme d'expression stable d'une phosphodiesterase de camp a affinite elevee et son utilisation Download PDFInfo
- Publication number
- CA2277430A1 CA2277430A1 CA002277430A CA2277430A CA2277430A1 CA 2277430 A1 CA2277430 A1 CA 2277430A1 CA 002277430 A CA002277430 A CA 002277430A CA 2277430 A CA2277430 A CA 2277430A CA 2277430 A1 CA2277430 A1 CA 2277430A1
- Authority
- CA
- Canada
- Prior art keywords
- enzyme
- pde
- rolipram
- camp
- iva
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
On a déterminé une lignée cellulaire CHO-K1 exprimant de façon stable une enzyme humaine PDE IVa de recombinaison à longueur totale (rhPDEIVa) par sélection d'hygromycine B. On a évalué l'inhibition de l'activité de PDE IVa exprimée par des inhibiteurs sélectifs de PDE IV. L'ordre de classification des puissances des inhibiteurs en élevant cAMP dans la méthode de détermination de cellules entières s'est avéré totalement différent de celui obtenu avec l'enzyme soluble. L'ordre de classification des puissances s'est également maintenu quand on a mesuré des rapports d'activité de PKA à la place de niveaux de cAMP. Quand on a examiné l'inhibition de l'activité de PDE IVa soluble en présence de 100 mM de MgCl¿2?, l'ordre de classification des puissances des inhibiteurs s'est avéré être identique à celui qu'on avait obtenu pour les méthodes de détermination de cellules entières (à la fois cAMP et PLA). La conformation observée d'affinité élevée de l'enzyme ne dépendait pas d'un cation ou d'un anion spécifique. Le déplacement de sensibilité de l'enzyme rhPDE IVa pour (R)-rolipram en présence d'une force ionique accrue était accompagné par une capacité améliorée de la préparation d'enzyme soluble à se fixer de façon spécifique et avec une affinité élevée à [3H](R)-rolipram.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3469197P | 1997-01-09 | 1997-01-09 | |
US60/034,691 | 1997-01-09 | ||
GBGB9705910.9A GB9705910D0 (en) | 1997-03-21 | 1997-03-21 | System for stably expressing a high-affinity cAMP phosphodiesterase and use thereof |
GB9705910.9 | 1997-03-21 | ||
US6542097P | 1997-11-13 | 1997-11-13 | |
US60/065,420 | 1997-11-13 | ||
PCT/CA1998/000024 WO1998030718A1 (fr) | 1997-01-09 | 1998-01-07 | Systeme d'expression stable d'une phosphodiesterase de camp a affinite elevee et son utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2277430A1 true CA2277430A1 (fr) | 1998-07-16 |
Family
ID=27268783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002277430A Abandoned CA2277430A1 (fr) | 1997-01-09 | 1998-01-07 | Systeme d'expression stable d'une phosphodiesterase de camp a affinite elevee et son utilisation |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2277430A1 (fr) |
WO (1) | WO1998030718A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6368815B1 (en) * | 1999-03-29 | 2002-04-09 | Warner-Lambert Company | Screening of molecules that inhibit human phosphodiesterase 4A produced by non-recombinant cell lines |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW263495B (fr) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
DE69434492T2 (de) * | 1993-03-10 | 2006-07-13 | Smithkline Beecham Corp. | Phosphodiesterase des menschlichen gehirns |
JPH08511805A (ja) * | 1993-06-18 | 1996-12-10 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
GB9412571D0 (en) * | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB2301363B (en) * | 1994-12-23 | 1998-12-30 | Celltech Therapeutics Ltd | Human phosphodiesterase type ivc and its production and use |
GB9603723D0 (en) * | 1996-02-22 | 1996-04-24 | Merck & Co Inc | Diphenyl pyridyl derivatives as pde iv inhibitors |
-
1998
- 1998-01-07 CA CA002277430A patent/CA2277430A1/fr not_active Abandoned
- 1998-01-07 WO PCT/CA1998/000024 patent/WO1998030718A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1998030718A1 (fr) | 1998-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Biondi et al. | Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA | |
O'CONNELL et al. | The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5) | |
Bamette et al. | Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H] rolipram binding | |
Vullo et al. | Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides—a new target for the design of antitumor and antiglaucoma drugs? | |
Michel et al. | PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex | |
Boularan et al. | Cardiac cAMP: production, hydrolysis, modulation and detection | |
Shepherd et al. | Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells | |
Saldou et al. | Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors | |
MacKenzie et al. | Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation | |
Wang et al. | Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7 | |
Kenan et al. | Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms | |
US5922557A (en) | System for stably expressing a high-affinity camp phosphodiesterase and use thereof | |
Nolan et al. | Kinetic analysis of human flap endonuclease-1 by flow cytometry | |
Kovala et al. | Recombinant Expression of a Type IV, cAMP-Specific Phosphodiesterase: Characterization and Structure− Function Studies of Deletion Mutants | |
Shepherd et al. | Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform | |
Perrino et al. | Substrate selectivity and sensitivity to inhibition by FK506 and cyclosporin A of calcineurin heterodimers composed of the α or β catalytic subunit | |
Katayama et al. | Critical determinants of substrate recognition by cyclin-dependent kinase-like 5 (CDKL5) | |
Laffargue et al. | Phosphoinositide 3‐kinase and integrin signalling are involved in activation of Bruton tyrosine kinase in thrombin‐stimulated platelets | |
Ogris et al. | Catalytically inactive protein phosphatase 2A can bind to polyomavirus middle tumor antigen and support complex formation with pp60c-src | |
Walker et al. | Protein kinase C chimeras: catalytic domains of alpha and beta II protein kinase C contain determinants for isotype-specific function. | |
POOLEY et al. | Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines | |
Ireton et al. | Expression of human topoisomerase I with a partial deletion of the linker region yields monomeric and dimeric enzymes that respond differently to camptothecin | |
Kahlos et al. | Thioredoxin restores nitric oxide-induced inhibition of protein kinase C activity in lung endothelial cells | |
US6329137B1 (en) | Intact cell assay for protein tyrosine phosphatases using recombinant baculoviruses | |
Weeks et al. | N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |